Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Pacira BioSciences, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
PCRX
Nasdaq
2834
www.pacira.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Pacira BioSciences, Inc.
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Feb 6th, 2025 1:00 pm
Should You Buy Pacira (PCRX) After Golden Cross?
- Feb 5th, 2025 2:55 pm
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
- Feb 3rd, 2025 2:50 pm
Pacira Announces Updates to Board of Directors
- Jan 30th, 2025 1:00 pm
Pacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments
- Jan 21st, 2025 1:00 pm
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
- Jan 17th, 2025 2:50 pm
PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales
- Jan 13th, 2025 4:43 pm
Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization
- Jan 10th, 2025 1:00 pm
Pacira BioSciences Secures FDA Approval For New iovera SmartTip to Manage Chronic Low Back Pain
- Jan 7th, 2025 4:49 pm
Pacira BioSciences Receives FDA 510k Clearance for New iovera° SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block
- Jan 7th, 2025 1:00 pm
Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Jan 2nd, 2025 9:01 pm
Here's Why Pacira (PCRX) is a Strong Momentum Stock
- Dec 18th, 2024 2:50 pm
DOMA Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira BioSciences, Inc.
- Dec 11th, 2024 1:05 pm
Pacira Awarded New U.S. Patent Covering EXPAREL Composition
- Dec 3rd, 2024 12:30 pm
Why Pacira (PCRX) is a Top Momentum Stock for the Long-Term
- Nov 29th, 2024 2:50 pm
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
- Nov 14th, 2024 3:05 pm
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
- Nov 12th, 2024 1:00 pm
Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth
- Nov 7th, 2024 3:09 pm
Q3 2024 Pacira Biosciences Inc Earnings Call
- Nov 7th, 2024 1:49 pm
Pacira BioSciences Inc (PCRX) Q3 2024 Earnings Call Highlights: Strong Financial Position ...
- Nov 7th, 2024 7:20 am
Scroll